Expression profile,clinical significance,and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non

Abstract

Insulin-like growth factor 2 messenger RNA-binding proteins have been described to associate with malignant process in many cancers. However, the role of insulin-like growth factor 2 messenger RNA-binding protein family has not been thoroughly elucidated in non–small cell lung cancer. This study was to investigate the expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins family in non–small cell lung cancer. The expression levels of IGF2BP1–IGF2BP3 in tumor and adjacent normal tissues were determined, and association with clinicopathological features and overall survival was investigated by analyzing The Cancer Genome Atlas lung cancer database. Proliferation, migration, invasion assays, and flow-cytometry analysis were used to investigate the biological function in vitro. Insulin-like growth factor 2 messenger RNA-binding protein expression levels were significantly increased in non–small cell lung cancer compared to adjacent normal lung tissues. Chi-square test indicated that IGF2BP1 and IGF2BP3 expressions correlated with some meaningful clinical characteristics in non–small cell lung cancer. Kaplan–Meier analysis showed that high-level expression of IGF2BP1 or IGF2BP3 predicted poor overall survival in lung adenocarcinoma patients. Multivariate regression analysis showed that high level of IGF2BP3 was an independent risk factor for poor prognosis in lung adenocarcinoma patients (hazard ratio = 1.616, p = 0.017). In vitro, knockdown of IGF2BP3 inhibited lung adenocarcinoma cell proliferation by inducing cell cycle arrest and apoptosis, and undermined abilities of migration and invasion, and overexpression of IGF2BP3 could promote malignant phenotypes in lung adenocarcinoma cells. Our study revealed that expression of insulin-like growth factor 2 messenger RNA-binding proteins was widely upregulated and correlated with some certain clinicopathological features in non–small cell lung cancer. Especially, in insulin-like growth factor 2 messenger RNA-binding protein family, IGF2BP3 might play the most important role in tumor aggressiveness and prognosis in lung adenocarcinoma, and IGF2BP3 might serve as a potential therapeutic target and a novel prognostic biomarker in lung adenocarcinoma patients.

Keywords

Insulin-like growth factor 2 messenger RNA-binding proteins non–small cell lung cancer The Cancer Genome Atlas prognosis

Introduction

Lung cancer is the most common malignancy worldwide, and it also acts as the leading cause of cancer-related death.¹ Two main histological subtypes are included: non–small cell lung cancer (NSCLC) and small cell lung cancer. NSCLC contributes to about 85% of all lung cancers, and lung adenocarcinoma (LUAD) has become the most common type of NSCLC in recent years.^1,2 In spite of advances in lung cancer therapies, prognosis of NSCLC is still unfavorable, with an overall 5-year survival rate less than 15%.³ Therefore, effective prognostic biomarkers and potential drug targets are eagerly needed.

RNA-binding proteins (RBPs) bind to specific motifs in RNA structures to exert their roles in various biological processes.⁴ Dysfunction of RBPs causes diseases, such as neural disease, metabolic disease, and cancer.^5,6 Insulin-like growth factor 2 messenger RNA-binding proteins (IGF2BPs), also known as IMPs, are evolutionally conserved RBPs in metazoan genomes. These proteins contain evolutionally conserved RNA recognition motif 1 domains and K homology domains.⁷ IGF2BP1 is the best-studied IGF2BP. IGF2BP1 acts in various important biological pathways, such as RNA location, translation, and stability.^8–10 IGF2BP1 was reported to promote proliferation,^11,12 invasion,^11,13 and chemoresistance¹⁴ in various cancers, and overexpression of IGF2BP1 predicts poor prognosis.^15,16 IGF2BP3 shows a high identity (73%) with IGF2BP1, and the two proteins share similar biological functions.⁷ IGF2BP3 has also been proposed as a oncofetal protein in a variety of cancers including LUAD.¹⁷ Moreover, IGF2BP3 overexpression also predicts poor prognosis in endometrial carcinoma,¹⁸ ovarian cancer,¹⁹ oral squamous cell carcinoma,²⁰ and colorectal cancer.²¹ As for IGF2BP2, the clinical role has also been investigated in several cancers, such as colorectal cancer,²² hepatocellular carcinoma,²³ breast cancer,²⁴ and embryonal rhabdomyosarcoma.²⁵ Although IGF2BPs have been widely investigated in a variety of cancers, comprehensive analysis on IGF2BP family in NSCLC has never been performed.

In this study, for the first time, we performed systematic analysis of IGF2BP family in NSCLC. Results indicated that IGF2BPs are widely upregulated in NSCLC, and IGF2BP3 overexpression is the only independent risk factor for poor prognosis in LUAD patients. In addition, we also explore biological significance of IGF2BP3 in LUAD cells. Our findings suggest that IGF2BPs, especially IGF2BP3, play a significant role in LUAD progression and predict poor prognosis for LUAD patients.

Materials and methods

Data sources and bioinformatics

TCGA_LUAD_exp_HiSeqV2-2015-02-24 and TCGA_LUSC_exp_HiSeqV2-2015-02-24 were downloaded at the website of the UCSC cancer browser (http://genome-cancer.ucsc.edu).^26,27 These data were obtained using the next-generation sequencing IlluminaHiSeq platform, containing 511 and 502 pathologically diagnosed lung cancer tissue samples with corresponding 58 and 51 paired normal lung tissue samples, respectively. A total of 400 out of 511 LUAD patients and 409 out of 502 lung squamous cell carcinoma (LUSC) patients with full-scale clinical data and follow-up information were chosen for further investigation. Values for IGF2BP expression were obtained from the “genomicMatrix” file, and all messenger RNA (mRNA) expression values were normalized. Then, in order to pick out appropriate cell lines for functional research, the Cancer Cell Line Encyclopedia (http://www.broadinstitute.org/ccle/home)²⁸ was used, and the expression of IGF2BP3 in LUAD cells was evaluated.

Tissue collection and immunohistochemistry

In this study, paired samples of NSCLC tissues and adjacent normal tissues from patients who underwent surgical resection at the Affiliated Cancer Hospital of Nanjing Medical University (Nanjing, China) from 2013 to 2015. Informed written consent for scientific use of biological material was obtained from each patient, and this study was approved by the Ethics Committee of Cancer Institute of Jiangsu Province. Immunohistochemistry (IHC) for IGF2BP expression in samples was performed using standard methods. Briefly, tissue sections were deparaffinized and rehydrated through graded alcohol. Endogenous peroxidase activity was blocked by incubation in 3% H₂O₂. Antigen retrieval was carried out with 0.01 M citrate buffer (pH 6.0) and microwave heat induction. Staining was scored by blinded observers (including a pathologist) according to intensity and percentage of positive cells.

Cell lines, cell culture, and transfection

H1299, H1975, and A549 cells were obtained from American Type Culture Collection (ATCC, USA), and human bronchial epithelial cell (HBE) was gifted by Dr Zhibin Hu. All cells were grown in RPMI 1640 media (KeyGEN, Nanjing, China) supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin and cultured at 37°C in a humidified incubator containing 5% CO₂. Transfection was performed following the small-interfering RNA (siRNA) sequences transfection protocol for Lipofectamine RNAiMAX (Invitrogen, USA). Nonsense RNA (nsRNA) was used as a negative control for IGF2BP3 siRNA. Transfection efficiency was evaluated by quantitative real-time polymerase chain reaction (PCR) and western blot. Two siRNAs were designed: The sequences were as follows: siRNA-1 for IGF2BP3: 5′-GCUGCUGAGAAGUCGAUUATT-3′ (sense), 5′-UAAUCGACUUCUCAGCAGCTT-3′ (antisense); siRNA-2 for IGF2BP3: 5′-CUUUGUUAGUCCUAAAGAATT-3′ (sense), 5′-UUCUUUAGGACUAACAAAGTT-3′ (antisense). And the following nonsense siRNA was used as negative control: 5′-UUCUCCGAACGUGUCACGUTT-3′ (sense), 5′-ACGUGACACGUUCGGAGAATT-3′ (antisense). IGF2BP3 complementary DNA (cDNA) was cloned into a pEGFP-N1 vector (purchased from Genechem) to construct overexpression plasmid, and an empty vector (EV) was used as a negative control.

RNA preparation, reverse transcription, and quantitative real-time polymerase chain reaction

Total RNA was extracted from cultured cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instruction. For real-time polymerase chain reaction (RT-PCR), 1000 ng total RNA was reverse-transcribed to a final volume of 20 µL cDNA using a Reverse Transcription Kit (Takara, Dalian, China; cat: RR036A). Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was performed with SYBR Select Master Mix (Applied Biosystems, Foster City, CA, USA; cat: 4472908). The primers for IGF2BP3 and β-actin are as follows: IGF2BP3 forward, 5′-CACATCAAGCAGCTTTCTCG-3′, and reverse, 5′-CCTCTGGTGGTCCAGTGATAA-3′; β-actin forward, 5′-TGACGTGGACATCCGCAAAG-3, and reverse, 5′-CTGGAAGGTGGACAGCGAGG-3. The qRT-PCR data collection was performed using a QuantStudio^™ 6 Flex Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), and the qRT-PCR reaction included an initial denaturation step at 95°C for 10 min, followed by 40 cycles of 92°C for 15 s and 60°C for 1 min. Each sample was run in triplicate, and the relative expression was calculated and normalized using the 2^−ΔΔCt method.

Cell proliferation assay

The cell proliferation was monitored using a Cell Counting Kit-8 (CCK-8; KeyGEN). Cells were plated in 96-well plates at a density of 2000 cells in 100 µL/well, and the absorbance was measured at 450 nm with an ELx-800 Universal Microplate Reader (BioTek, Winooski, VT, USA). Each experiment was repeated in quadruplicate independently.

For colony formation assay, a total of 100 transfected cells were placed in a fresh six-well plate and maintained in media containing 10% FBS, replacing medium every 3 or 4 days. After 2 weeks, cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Visible colonies were then counted. For each treatment group, wells were assessed in triplicate.

Flow-cytometry analysis

Flow-cytometry analysis was performed to detect cell cycle distribution and cell apoptosis. For cell cycle distribution, cells were transferred and fixed in centrifuge tubes containing 4.5 mL of 70% ethanol on ice. The cells were kept in ethanol for at least 2 h at 4°C. Then, the ethanol-suspended cells were centrifuged for 5 min at 300g. Cell pellets were re-suspended in 5 mL of phosphate-buffered saline (PBS) for approximately 30 s and centrifuged at 300g for 5 min, and then re-suspended in 1 mL of propidium iodide (PI) staining solution and kept in the dark at 37°C for 10 min. Samples were analyzed using a FACSCalibur flow cytometer. The percentage of the cells in G0/G1, S, and G2/M phase were counted and compared.

For apoptosis analysis, cells were washed and re-suspended at a concentration of 1 × 10⁶ cells/mL. Then, an Annexin V-FITC Apoptosis Detection Kit (BD Biosciences) was used following the manufacturer’s protocol. After incubation at room temperature in dark for 20 min, the cells were immediately analyzed by a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). All samples were assayed in triplicate.

Cell invasion and migration assay

For migration assay, transfected cells (40,000 cells in 100 µL per well) were plated in the upper chamber of transwell assay inserts (8 mm pores; Millipore, Billerica, MA, USA) containing 200 µL of serum-free RPMI 1640 media. The lower chambers were filled with RPMI 1640 containing 10% FBS. After 24 h of incubation, cells on the filter surface were fixed with methanol, stained with crystal violet, and photographed. Migration was assessed by counting the number of stained cell nuclei from five random fields per filter in each group.

For invasion assay, transfected cells (40,000 cells in 100 µL per well) were plated in the top chamber with a Matrigel-coated membrane (BD Biosciences) in 300 µL serum-free RPMI 1640. The bottom chambers were filled with RPMI 1640 containing 10% FBS. Invasion was determined after 48 h of incubation.

Statistical analysis

All statistical analyses were performed using SPSS Statistics (version 20.0, Chicago, IL, USA) and GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). The results were presented as mean ± standard deviation (SD). Relative quantification of mRNA expression level was calculated with the 2^−ΔΔCt method. Student’s t test was used to analyze difference between the two groups. Association of IGF2BP expression with clinicopathological parameters was analyzed using chi-square test. Cox univariate and multivariate regression was used to evaluate prognostic value of each parameter. Association of IGF2BP3 expression with other mRNAs was analyzed using Pearson’s correlation test. A p value <0.05 was considered statistically significant.

Results

IGF2BPs are widely upregulated in NSCLC

By analyzing TCGA_LUAD_exp_HiSeqV2-2015-02-24 and TCGA_LUSC_exp_HiSeqV2-2015-02-24 datasets, compared with normal tissues, IGF2BPs were found to be widely upregulated in NSCLC tissues. All data were presented as mean ± SD in Table 1. We observed that except IGF2BP2 in LUAD tissues (fold change: 1.022, p = 0.4040), each IGF2BP was significantly overexpressed in both LUAD and LUSC tissues compared with normal tissues. In LUAD, IGF2BP1 is 3.95-fold upregulated and IGF2BP3 is 1.50-fold upregulated. In LUSC, IGF2BP1 is 4.33-fold, IGF2BP2 is 1.24-fold, and IGF2BP3 is 1.86-fold with all the p values <0.0001 (Figure 1(a)–(f)).

Table 1.

Expression profile of IGF2BP family in LUAD and LUSC.

Gene symbol	Term
Gene symbol	Tumor tissues(Value in TCGA)	Normal tissues(Value in TCGA)	Fold change(Tumor vs normal)	p value(Unpaired t test)
LUAD
IGF2BP1	3.614 ± 0.1461	0.914 ± 0.1385	3.954	<0.0001
IGF2BP2	8.289 ± 0.07256	8.108 ± 0.07606	1.022	0.4040
IGF2BP3	7.467 ± 0.1072	4.991 ± 0.1157	1.496	<0.0001
LUSC
IGF2BP1	5.727 ± 0.1477	1.322 ± 0.1188	4.332	<0.0001
IGF2BP2	10.25 ± 0.08030	8.262 ± 0.05870	1.241	<0.0001
IGF2BP3	9.200 ± 0.08843	4.939 ± 0.08465	1.863	<0.0001

IGF2BP: insulin-like growth factor 2 mRNA-binding proteins; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; TCGA: The Cancer Genome Atlas.

Figure 1.

IGF2BPs are significantly upregulated in LUAD and LUSC. (a) IGF2BP1 in LUAD (FC = 3.954, p < 0.0001). (b) IGF2BP2 in LUAD (FC = 1.022, p = 0.4040). (c) IGF2BP3 in LUAD (FC = 1.496, p < 0.0001). (d) IGF2BP1 in LUSC (FC = 4.332, p < 0.0001). (e) IGF2BP2 in LUSC (FC = 1.241, p < 0.0001). (f) IGF2BP3 in LUSC (FC = 1.863, p < 0.0001). (g) IHC analysis showed that IGF2BP levels were significantly increased in tumor tissues compared with adjacent normal tissues.

IHC was performed to evaluate the IGF2BP expression in the tumor tissues and adjacent normal tissues. As shown in Figure 1(g), IGF2BP levels were found to be significantly increased in the tumor tissues compared with adjacent normal tissues.

Correlation between IGF2BP expression with clinicopathological features in LUAD and LUSC

After further analyzing the file “clinical_data” in TCGA_LUAD_exp_HiSeqV2-2015-02-24 and TCGA_LUSC_exp_HiSeqV2-2015-02-24 datasets, 400 LUAD patients and 409 LUSC patients with full-scale clinical data were picked out. Among the 400 LUAD patients and 409 LUSC patients, we chose median expression values of IGF2BPs as the cutoff value, and 400 LUAD patients were divided into two groups each time: high-level IGF2BP (1–3) and low-level IGF2BP (1–3), so were the 409 LUSC patients. Then, we explored relationship between IGF2BP expression and clinicopathological features in both LUAD and LUSC. The most meaningful founding is that high-level IGF2BP3 was significantly correlated with bigger primary tumor size (p = 0.0445), lymph node metastasis (p = 0.0093), and advanced tumor stage (p = 0.0187) in LUAD (Table 2). In addition, IGF2BP1 overexpression was found to be significantly correlated with bigger tumor size (p = 0.0032) in LUAD and younger age (p = 0.0070) in LUSC (Table 3). However, no significant correlation of IGF2BP2 was observed with any clinical feature in LUAD or LUSC (Table 4).

Table 2.

Correlation between IGF2BP3 expression and clinical characteristics in TCGA datasets.

Characteristics	LUAD			LUSC
Characteristics	Low	High	p value	Low	High	p value
Age at diagnosis (years)			0.8412			0.0939
⩽65	93	95		68	84
>65	107	105		137	120
Sex			0.0882			0.9354
Male	84	101		149	149
Female	116	99		56	55
Primary tumor size			0.0445*			0.4635
T1	76	53		48	39
T2	102	118		119	130
T3–T4	22	29		38	35
Lymph node status			0.0093*			0.2441
Negative	140	115		135	123
Positive	60	85		70	81
Tumor stage			0.0187*			0.4744
I	118	91		104	92
II	47	56		62	72
III–IV	35	53		39	40

TCGA: The Cancer Genome Atlas; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma.

Significant correlation.

Table 3.

Correlation between IGF2BP1 expression and clinical characteristics in TCGA datasets.

Characteristics	LUAD			LUSC
Characteristics	Low	High	p value	Low	High	p value
Age at diagnosis (years)			0.8412			0.0070*
⩽65	93	95		63	89
>65	107	105		142	115
Sex			0.0882			0.7616
Male	84	101		148	150
Female	116	99		57	54
Primary tumor size			0.0032*			0.6755
T1	79	48		40	47
T2	100	121		127	122
T3–T4	21	31		38	35
Lymph node status			0.4666			0.4502
Negative	131	124		133	125
Positive	69	76		72	79
Tumor stage			0.0901			0.9080
I	115	94		100	96
II	48	55		67	67
III–IV	37	51		38	41

TCGA: The Cancer Genome Atlas; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma.

Significant correlation.

Table 4.

Correlation between IGF2BP2 expression and clinical characteristics in TCGA datasets.

Characteristics	LUAD			LUSC
Characteristics	Low	High	p value	Low	High	p value
Age at diagnosis (years)			0.6886			0.7104
⩽65	92	96		78	74
>65	108	104		127	130
Sex			0.2700			0.9354
Male	87	98		149	149
Female	113	102	0.3670	56	55
Primary tumor size						0.1788
T1	70	57		50	37
T2	106	115		116	133
T3–T4	24	28		39	34
Lymph node status			0.9172			0.3371
Negative	127	128		134	124
Positive	73	72		71	80
Tumor stage			0.1006			0.1959
I	106	103		102	94
II	58	45		59	75
III–IV	36	52		44	35

TCGA: The Cancer Genome Atlas; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma.

Prognostic significance of IGF2BPs in LUAD and LUSC patients

As shown above, mRNA expression of IGF2BPs was upregulated in lung cancer tissues compared with normal tissues, and only IGF2BP1 and IGF2BP3 exhibited clinically meaningful correlation in LUAD patients. To evaluate the clinical utility of IGF2BPs in prognosis of NSCLC patients, we used Kaplan–Meier analysis and log-rank test to evaluate overall survival (OS) for IGF2BPs in LUAD and LUSC patients, respectively. As shown in Figure 2(a)–(c), LUAD patients with higher IGF2BP1 or IGF2BP3 expression exhibited poor OS (IGF2BP1-high: hazard ratio (HR) = 1.544, p = 0.0137; IGF2BP3-high: HR = 1.898, p = 0.0003), but no significant level was reached in higher IGF2BP2 patients (HR = 1.299, p = 0.2375). However, no significant association with OS was found in LUSC patients when comparing each IGF2BP-high and IGF2BP-low group (IGF2BP1-high: HR = 0.8125, p = 0.1772; IGF2BP2-high: HR = 0.9609, p = 0.7958; IGF2BP3-high: HR = 0.8448, p = 0.2746; Figure 2(d)–(f)).

Figure 2.

High-level expression of IGF2BP1 and IGF2BP3 predicts poor prognosis in LUAD patients. (a) High-IGF2BP1 in LUAD (HR = 1.544, p = 0.0137). (b) High-IGF2BP2 in LUAD (HR = 1.299, p = 0.2375). (c) High-IGF2BP3 in LUAD (HR = 1.898, p = 0.0003). (d) High-IGF2BP1 in LUSC (HR = 0.8125, p = 0.1772). (e) High-IGF2BP2 in LUSC (HR = 0.9609, p = 0.7958). (f) High-IGF2BP3 in LUSC (HR = 0.8448, p = 0.2746).

To further evaluate the prognostic value of IGF2BPs in LUAD, we performed univariate and multivariate regression analysis. Univariate analysis revealed that in LUAD patients, advanced T status (p = 0.042), positive lymph node status (p < 0.001), advanced tumor, lymph node, metastasis (TNM) stage (p < 0.001), higher IGF2BP1 (p = 0.014), and higher IGF2BP3 (p < 0.001) were significantly associated with poor OS. After multivariate regression analysis, we found that only advanced TNM stage (HR = 2.275, p = 0.007) and high-expression level of IGF2BP3 (HR = 1.616, p = 0.017) were two independent risk factors for OS in LUAD patients. The resulting data were shown in Table 5.

Table 5.

Cox regression analysis of overall survival in LUAD patients in TCGA dataset.

	Univariate analysis			Multivariate analysis
	HR	p value	95% CI	HR	p value	95% CI
Gender (male vs female)	1.131	0.487	0.800–1.598	–	–	–
Age (years; >65 vs ⩽65)	0.985	0.931	0.695–1.395	–	–	–
Primary tumor size (T2–T4 vs T1)	1.545	0.042*	1.015–2.353	0.978	0.924	0.623–1.537
Lymph node status (positive vs negative)	2.810	<0.001*	1.974–3.999	1.397	0.241	0.799–2.440
TNM stage (stage II–IV vs stage I)	3.104	<0.001*	2.128–4.527	2.275	0.007*	1.249–4.144
IGF2BP1 (high vs low)	1.553	0.014*	1.091–2.211	1.335	0.127	0.921–1.937
IGF2BP2 (high vs low)	1.232	0.238	0.871–1.743	–	–	–
IGF2BP3 (high vs low)	2.092	<0.001*	1.455–3.008	1.616	0.017*	1.089–2.396

LUAD: lung adenocarcinoma; TCGA: The Cancer Genome Atlas; HR: hazard ratio; CI: confidence interval; TNM: tumor, lymph node, metastasis.

Significant correlation.

Knockdown of IGF2BP3 inhibits LUAD cell proliferation and motility, and induces cell cycle arrest and apoptosis in vitro

In consideration of the most clinically meaningful value of IGF2BP3 in LUAD, we next explored its biological function in LUAD cells. In order to choose appropriate cellular model for further investigation, we compared the expression of IGF2BP3 in different LUAD cell lines. H1299 and A549 cell lines were picked out because of highest expression (Figure 3(a) and (b)). The Cancer Cell Line Encyclopedia website also exhibited similar results. To investigate the biological function of IGF2BP3 in vitro, two different effective siRNAs (siRNA-1 and siRNA-2) were constructed and used to knockdown IGF2BP3. Knockdown efficiency was determined by qRT-PCR and western blot (Figure 3(c) and (d)).

Figure 3.

Knockdown of IGF2BP3 inhibits LUAD cell proliferation and motility, and induces cell cycle arrest and apoptosis in vitro. (a and b) IGF2BP3 mRNA expression was increased in LUAD cell lines, and H1299 and A549 were chosen as appropriate cellular models due to their highest expression. (c and d) Two different effective siRNAs (siRNA-1 and siRNA-2) were used to knockdown IGF2BP3 in H1299 and A549 cells. The transfection efficiency was determined by qRT-PCR and western blot. (e and f) Knockdown of IGF2BP3 inhibited both H1299 and A549 cells proliferation. (g and h) Colony numbers of H1299 and A549 cells transfected with si-IGF2BP3 were less than those transfected with si-NC. (i–l) Migration and invasion abilities of H1299 or A549 cells transfected with si-IGF2BP3 was inhibited compared with NC group. (m and n) H1299 and A549 cells transfected with si-IGF2BP3 exhibited more arrest at G1 phase than those transfected with si-NC. (o and p) Knockdown of IGF2BP3 induced apoptosis of both H1299 and A549 cells after 48 h of transfection.

As shown in Figure 3(e) and (f), CCK-8 assay revealed that knockdown of IGF2BP3 inhibited proliferation of both H1299 and A549 cells. Moreover, si-IGF2BP3 transfected cells had fewer colonies than those transfected with negative control siRNA (si-NC; Figure 3(g) and (h)). The transwell assay showed that migration ability of H1299 and A549 cells was inhibited by siRNA-mediated knockdown of IGF2BP3 (Figure 3(i) and (j)), and the Matrigel invasion assay also yielded similar results (Figure 3(k) and (l)). Finally, the effects of IGF2BP3 on cell cycle distribution and apoptosis were evaluated by flow-cytometry analysis. As shown in Figure 3(m) and (n), si-IGF2BP3 treatment increased more H1299 and A549 cells arrest in G1 phase compared to si-NC. Furthermore, knockdown of IGF2BP3 also induced more apoptosis of the two cell lines after 48 h of transfection (Figure 3(o) and (p)).

Overexpression of IGF2BP3 promotes LUAD cells malignant phenotypes in vitro

We chose H1975 cell line to perform overexpression experiment because of its lowest expression in LUAD cell lines (Figure 3(a) and (b)). As shown in Figure 4(a), CCK-8 assay showed that overexpression (OE) of IGF2BP3 promoted H1975 cells proliferation compared with empty vector (EV) group. Transfection efficiency was determined by western blot (Figure 4(b)). Moreover, more colonies were observed in OE group compared with EV group (Figure 4(c) and (d)). The migration and invasion assays showed that motility of H1975 cells was significantly increased by enforced overexpression of IGF2BP3 (Figure 4(e) and (f)). Flow-cytometry analysis showed that OE-IGF2BP3 could promote H1975 cells G1/S transition (Figure 4(g) and (h)), while no difference in apoptosis was observed between EV and OE group (Figure 4(i) and (j)).

Figure 4.

Overexpression of IGF2BP3 promotes malignant phenotypes of H1975 cells in vitro. (a) CCK-8 assay showed that overexpression (OE) of IGF2BP3 promoted H1975 cells proliferation compared with empty vector (EV) group. (b) Transfection efficiency was determined by western blot. (c and d) More colonies were observed in OE group compared with EV group. (e and f) Migration and invasion assays showed that motility of H1975 cells was significantly increased by enforced overexpression of IGF2BP3. (g and h) Flow-cytometry analysis showed that OE-IGF2BP3 could promote H1975 cells G1/S transition. (i and j) No difference in apoptosis was observed between EV and OE group.

Discussion

IGF2BPs were originally discovered in embryos and in transformed cells.^8,29 Although the fetal expression is prominent, some studies also indicated that the proteins are also present in mature tissues.^30,31 From a phylogenetic point of view, IGF2BP1 and IGF2BP3 are closely related, whereas IGF2BP2 diverged from the two other members at an earlier stage and may have acquired a distinct pattern of expression.³² Furthermore, IGF2BPs were demonstrated to enhance tumor growth, invasiveness, and chemoresistance, and closely associate with poor prognosis in various cancers.

In this study, we performed a systematic analysis on IGF2BP family in NSCLC. TCGA datasets and IHC analysis showed that IGF2BPs were significantly upregulated in LUAD and LUSC. In LUAD, the most meaningful founding was that IGF2BP3 overexpression was significantly associated with some important clinicopathological parameters such as bigger primary tumor size, lymph node metastasis, and advanced tumor stage. In addition, IGF2BP1 overexpression was also associated with bigger tumor size in LUAD. As for LUSC, IGF2BP1 overexpression was found to be associated with younger age. Except for these, no more significant association was detected.

Then, we analyzed prognostic value of IGF2BPs family in both LUAD and LUSC. Kaplan–Meier analysis and log-rank test were used to evaluate OS for IGF2BPs in LUAD and LUSC patients, respectively. As matched with clinical association analysis before, LUAD patients with higher IGF2BP1 or IGF2BP3 expression exhibited poor OS (IGF2BP1-high: HR = 1.544, p = 0.0137; IGF2BP3-high: HR = 1.898, p = 0.0003), and no significant level was reached in higher IGF2BP2 patients (HR = 1.299, p = 0.2375). However, no significant association with OS was found in LUSC patients when comparing each IGF2BP-high and IGF2BP-low group. Then, we performed univariate and multivariate regression analyses to further evaluate prognostic significance of IGF2BPs in LUAD. Multivariate analysis revealed that only higher expression level of IGF2BP3 and advanced TNM stage were proved to be two independent risk factors for OS in LUAD patients.

Consistent with clinical findings of IGF2BP3 in LUAD, experiments on LUAD cell lines showed that suppression of IGF2BP3 inhibited proliferation by inducing cell cycle arrest and apoptosis, and undermined abilities of migration and invasion, and overexpression of IGF2BP3 could promote malignant phenotypes in vitro.

In conclusion, IGF2BP1–IGF2BP3 were widely upregulated in NSCLC. Especially, in IGF2BP family, IGF2BP3 might play the most important role in tumor aggressiveness and prognosis in LUAD, and IGF2BP3 might serve as a potential therapeutic target and a novel prognostic biomarker in LUAD patients.

Footnotes

Acknowledgements

R.S., X.Y., and Y.W. contributed equally.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This work was supported by the Natural Science Foundation of Jiangsu Province (NO. BK2012482), National Natural Science Foundation of China (NO. 81472702), and Jiangsu Provincial Special Program of Medical Science (NO. BL2012030).

References

Chen

Zheng

Baade

. Cancer statistics in china, 2015. CA-Cancer J Clin 2016; 66: 115–132.

Kamangar

Dores

Anderson

. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137–2150.

Youlden

Cramb

Baade

. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008; 3: 819–831.

Moore

. From birth to death: the complex lives of eukaryotic mRNAs. Science 2005; 309: 1514–1518.

Lukong

Chang

Khandjian

. RNA-binding proteins in human genetic disease. Trends Genet 2008; 24: 416–425.

Musunuru

. Cell-specific RNA-binding proteins in human disease. Trends Cardiovasc Med 2003; 13: 188–195.

Bell

Wachter

Muhleck

. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci 2013; 70: 2657–2675.

Nielsen

Christiansen

Lykke-Andersen

. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999; 19: 1262–1270.

Weidensdorfer

Stohr

Baude

. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA 2009; 15: 104–115.

10.

Katz

. Regulation of local expression of cell adhesion and motility-related mRNAs in breast cancer cells by IMP1/ZBP1. J Cell Sci 2012; 125: 81–91.

11.

Gong

Ren

Zhang

. MicroRNAs-491-5p suppresses cell proliferation and invasion by inhibiting IGF2BP1 in non-small cell lung cancer. Am J Transl Res 2016; 8: 485–495.

12.

Rebucci

Sermeus

Leonard

. MiRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1. Mol Cancer 2015; 14: 79.

13.

Zhou

Zhang

. MiR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. Oncogene 2015; 34: 965–977.

14.

Faye

Beug

Graber

. IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene 2015; 34: 1532–1541.

15.

Bell

Turlapati

Liu

. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma. J Clin Oncol 2015; 33: 1285–1293.

16.

Shigemasa

Ohama

. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol 2004; 24: 671–678.

17.

Findeis-Hosey

Yang

Spaulding

. IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 2010; 41: 477–484.

18.

Fadare

Liang

Crispens

. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Hum Pathol 2013; 44: 1508–1515.

19.

Hsu

Shen

Huang

. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer 2015; 113: 414–424.

20.

Lin

Chen

Jeng

. Insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40: 699–705.

21.

Shantha Kumara

Kirchoff

Caballero

. Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; igf2bp3 holds promise as a specific immunotherapy target. Oncoscience 2015; 2: 607–614.

22.

Song

. IGF2BP2 promotes colorectal cancer cell proliferation and survival through interfering with RAF-1 degradation by miR-195. FEBS Lett 2016; 590: 1641–1650.

23.

Kessler

Laggai

Barghash

. IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death Dis 2015; 6: e1894.

24.

Liu

Wang

. Autoimmune response to IGF2 mRNA-binding protein 2 (IMP2/p62) in breast cancer. Scand J Immunol 2015; 81: 502–507.

25.

Zhang

Ramanujan

. Oncogenic NRAs, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway. Cancer Res 2013; 73: 3041–3050.

26.

Goldman

Craft

Swatloski

. The UCSC cancer genomics browser: update 2015. Nucleic Acids Res 2015; 43: D812–D817.

27.

Wong

Vaske

. The UCSC interaction browser: multidimensional data views in pathway context. Nucleic Acids Res 2013; 41: W218–W224.

28.

Cancer Cell Line Encyclopedia Consortium and Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets. Nature 2015; 528: 84–87.

29.

Mueller-Pillasch

Pohl

Wilda

. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999; 88: 95–99.

30.

Hansen

Hammer

Nielsen

. Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol Cell Biol 2004; 24: 4448–4464.

31.

Mori

Sakakibara

Imai

. Expression of mouse igf2 mRNA-binding protein 3 and its implications for the developing central nervous system. J Neurosci Res 2001; 64: 132–143.

32.

Hammer

Hansen

Byskov

. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 2005; 130: 203–212.

Expression profile,clinical significance,and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non–small cell lung cancer

Abstract

Keywords

Introduction

Materials and methods

Data sources and bioinformatics

Tissue collection and immunohistochemistry

Cell lines, cell culture, and transfection

RNA preparation, reverse transcription, and quantitative real-time polymerase chain reaction

Cell proliferation assay

Flow-cytometry analysis

Cell invasion and migration assay

Statistical analysis

Results

IGF2BPs are widely upregulated in NSCLC

Correlation between IGF2BP expression with clinicopathological features in LUAD and LUSC

Prognostic significance of IGF2BPs in LUAD and LUSC patients

Knockdown of IGF2BP3 inhibits LUAD cell proliferation and motility, and induces cell cycle arrest and apoptosis in vitro

Overexpression of IGF2BP3 promotes LUAD cells malignant phenotypes in vitro

Discussion

Footnotes

Acknowledgements

Declaration of conflicting interests

Funding

References